Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
VYNE Therapeutics Inc. (VYNE) had Weighted-Average Shares Outstanding (Diluted) of 42.59M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$0.50M |
|
$-39.83M |
|
-- |
|
$0.50M |
|
$44.14M |
|
$-43.64M |
|
$3.83M |
|
$-39.80M |
|
$-39.80M |
|
$-39.81M |
|
$-39.81M |
|
$-39.83M |
|
$-39.81M |
|
$-43.64M |
|
$-46.08M |
|
42.59M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
42.59M |
$-0.93 |
|
$-0.93 |
|
| Balance Sheet Financials | |
$64.44M |
|
$0.11M |
|
$2.47M |
|
$66.91M |
|
$14.82M |
|
-- |
|
-- |
|
$14.82M |
|
$52.09M |
|
$52.09M |
|
$52.09M |
|
14.83M |
|
| Cash Flow Statement Financials | |
$-33.97M |
|
$23.36M |
|
$-0.14M |
|
$30.67M |
|
$19.93M |
|
$-10.75M |
|
$3.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-8709.98% |
|
-8709.98% |
|
-9196.81% |
|
-7944.71% |
|
-7950.90% |
|
$-34.09M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-76.43% |
|
-76.43% |
|
-59.50% |
|
-76.43% |
|
$3.51 |
|
$-0.80 |
|
$-0.80 |
|